More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$24.27B
EPS
1.88
P/E ratio
14.3
Price to sales
3.93
Dividend yield
--
Beta
0.782018
Previous close
$120.27
Today's open
$119.48
Day's range
$118.05 - $121.43
52 week range
$89.25 - $132.60
show more
CEO
William J. Meur
Employees
2844
Headquarters
Wilmington, DE
Exchange
Nasdaq Global Select
Shares outstanding
203832492
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript
Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

INCY Wins European Commission Nod For Skin Disease Drug
Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.
Zacks Investment Research • Nov 17, 2026

Incyte says EU approves oral treatment for chronic skin disease
Incyte said on Monday the European Commission had approved its once-daily oral therapy for a type of chronic skin disease.
Reuters • Nov 16, 2026

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.
Business Wire • Nov 16, 2026

Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030
Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as potential sources of growth after 2029.
MarketBeat • Nov 11, 2026

Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
Seeking Alpha • Nov 10, 2026

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte's investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have completed surgery and adjuvant chemotherapy (ACT), incorporating Signatera as both a primary and seco.
Business Wire • Nov 10, 2026

2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers. “It is our honor to reco.
Business Wire • Nov 6, 2026

Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Wolfe Research Healthcare Conference on Tuesday, November 10, 2026 at 10:00 am (EST) Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 9:00 am (GMT) UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 1:20 pm (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and wi.
Business Wire • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Incyte Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.